Latest news with #T-Bact
Business Standard
14-05-2025
- Business
- Business Standard
GSK Pharma gains as Q4 PAT rises 35% YoY to Rs 260 cr; declares dividend of Rs 42/share
Glaxosmithkline Pharmaceutical advanced 3.21% to Rs 2,879.70 after the company's standalone net profit jumped 34.73% to Rs 260.14 crore on a 6.06% increase in revenue from operations to Rs 966.08 crore in Q4 FY25 over Q4 FY24. Profit before tax stood at Rs 354.90 crore, up 32.08% from Rs 268.71 crore in the same period last year. Total expenses declined 3.53% YoY to Rs 650.64 crore. Notably, the cost of materials consumed dropped 43.65% YoY to Rs 108.35 crore, while employee benefits expense fell 11.49% to Rs 152.97 crore. On a full-year basis, the company's net profit jumped 57.19% to Rs 919.06 crore on a 9.28% rise in revenue to Rs 3,723.49 crore in FY25 over FY24. Bhushan Akshikar, managing director of GlaxoSmithKline Pharmaceuticals, said, Our diversified portfolio of general medicines, specialty, and vaccines has shown improved growth due to sustained innovation, enhanced healthcare professional (HCP) engagement, and rapid digital acceleration. This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers. Our key brands, including Augmentin, Calpol, Ceftum, T-Bact, and Trelegy, have played a significant role in driving growth throughout the year. Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country. The company said it is on track to launch Zejula (Niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (Dostarlimab), an immunotherapy for second-line treatment of endometrial cancer. Meanwhile, the board recommended a final dividend of Rs 42 per equity share for FY25, subject to shareholder approval at the companys 100th Annual General Meeting. GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies.
&w=3840&q=100)
Business Standard
13-05-2025
- Business
- Business Standard
GSK Pharma Q4 profit rises 35% to ₹263 crore on strong brand growth
GlaxoSmithKline (GSK) Pharmaceuticals on Tuesday announced a 35 per cent year-on-year (YoY) increase in consolidated net profit for the March quarter (Q4FY25) to ₹262.87 crore, up from ₹194.48 crore in the same period last year. The company's revenue from operations rose 4.8 per cent YoY to ₹974.37 crore, from ₹929.80 crore in Q4FY24. The performance is attributed to strong growth across key product portfolios. Sequentially, the company's net profit declined 14.3 per cent, while revenue rose 2.6 per cent from ₹229.88 crore and ₹949.42 crore, respectively, reported in Q3FY25. GSK Pharma said that flagship brands within its general medicines portfolio — including Augmentin, Calpol, Ceftum and T-Bact — strengthened their market positions with share gains. Bhushan Ashikar, Managing Director, GSK Pharma, said the company's diversified portfolio of general medicines, specialty products and vaccines had shown improved growth due to sustained innovation, enhanced healthcare professional (HCP) engagement and rapid digital acceleration. 'This has enhanced reach, expanded coverage, and provided a seamless omnichannel experience for our customers,' he added. Ashikar stated that the company will continue to focus on its innovative portfolio through the launch of oncology assets in the financial year (FY) 2025–26. 'The company is on track to launch Zejula (niraparib), a PARP inhibitor for ovarian cancer, and Jemperli (dostarlimab), an immunotherapy approved for the second-line treatment of endometrial cancer,' GSK Pharma said in a public statement. In the vaccines segment, the company maintained its leadership within the private market, with its paediatric vaccines portfolio — including Boostrix, Varilrix and Havrix — despite inclusion in the National Immunisation Programme (NIP) and rising competition. 'Shingrix is experiencing increased adoption, driven by heightened awareness and our efforts to develop the adult vaccination ecosystem in the country,' the company said. On Tuesday, GSK Pharma's stock rose 2.49 per cent, ending the day's trade at ₹2,789 on the Bombay Stock Exchange (BSE).
